2 weeks Ago By Defense World Staff
Prudential Financial Inc. trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 8.
1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,870 shares of the company’s stock after selling 427 shares during the quarter. Prudential Financial Inc.
’s holdings in Medpace were worth $1,618,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. R Squared Ltd bought a new position in shares of Medpace in the 4th quarter valued at $30,000.
SBI Securities Co. Ltd. acquired a new position in Medpace in the 4th quarter worth about $31,000.
Jones Financial Companies Lllp raised its position in Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after purchasing an additional 110 shares during the last quarter.
Lindbrook Capital LLC boosted its stake in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares in the last quarter.
Finally, Assetmark Inc. grew its holdings in shares of Medpace by 20.1% during the fourth quarter.
Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after purchasing an additional 29 shares during the last quarter. Institutional investors own 77.
98% of the company’s stock. Medpace Price PerformanceShares of NASDAQ:MEDP opened at $287.11 on Friday.
The business’s 50-day moving average is $331.56 and its 200-day moving average is $337.49.
Medpace Holdings, Inc. has a 1 year low of $282.42 and a 1 year high of $459.
77. The company has a market capitalization of $8.75 billion, a price-to-earnings ratio of 22.
73, a P/E/G ratio of 3.81 and a beta of 1.45.
Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.
96 by $0.71. Medpace had a return on equity of 51.
48% and a net margin of 19.17%. Analysts anticipate that Medpace Holdings, Inc.
will post 12.29 EPS for the current year. Analyst Upgrades and DowngradesA number of brokerages recently issued reports on MEDP.
Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a report on Monday, March 24th. Leerink Partners started coverage on shares of Medpace in a report on Monday, March 24th. They set a “market perform” rating and a $330.
00 price target on the stock. Finally, Robert W. Baird boosted their price objective on shares of Medpace from $354.
00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company.
According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $376.30.Get Our Latest Research Report on MEDPAbout Medpace (Free Report)Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries.
Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.Read MoreFive stocks we like better than MedpaceInsider Selling Explained: Can it Inform Your Investing Choices?Conagra Stock Could Thrive as Tariffs Hit Other SectorsHow to Invest in Small Cap Stocks Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey FindsCD Calculator: Certificate of Deposit Calculator Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc.
(NASDAQ:MEDP – Free Report)..
